ERBB2 and neoplasm: They showed that the probability of false-negative results decreases with the number of biopsies (i.e., the number of tumor cells available for analysis), especially for FGFR2. In other studies, the authors showed the same for HER2/neu and programmed death ligand 1 (PD-L1) (Grabsch et al. 2010; Lordick et al. 2017; Schoemig-Markiefka et al. 2021).